Clinical Trial Update: A Trial to Evaluate the Optimal Dose of MV-LASV (V182-001) [Phase 1]

View source ↗

Summary

Phase 1 trial to evaluate the optimal dose of MV-LASV (V182-001) for Lassa fever has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lassa Fever

Drugs mentioned

• MV-LASV (V182-001)

Snippet

Sponsor: Themis Bioscience GmbH | Conditions: Lassa Virus Infection | Phase 1 | Status: COMPLETED